Accepted Manuscript

Phase I-II trial of combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer

Amy E. Chang, Qian V. Wu, Isaac C. Jenkins, Jennifer M. Specht, Vijayakrishna K. Gadi, Julie R. Gralow, Lupe G. Salazar, Brenda F. Kurland, Hannah M. Linden

PII: S1526-8209(17)30280-X

DOI: 10.1016/j.clbc.2017.10.005

Reference: CLBC 693

To appear in: Clinical Breast Cancer

Received Date: 13 May 2017
Revised Date: 8 August 2017
Accepted Date: 1 October 2017

Please cite this article as: Chang AE, Wu QV, Jenkins IC, Specht JM, Gadi VK, Gralow JR, Salazar LG, Kurland BF, Linden HM, Phase I-II trial of combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer, *Clinical Breast Cancer* (2017), doi: 10.1016/j.clbc.2017.10.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Phase I-II trial of combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer

Amy E Chang¹, Qian V. Wu² Isaac C. Jenkins², Jennifer M. Specht^{1,3}, Vijayakrishna K. Gadi^{1,2,3}, Julie R. Gralow^{1,3}, Lupe G. Salazar^{1,3}, Brenda F Kurland⁴, Hannah M. Linden^{1,3}

- 1. University of Washington Department of Medicine
- 2. Fred Hutchinson Cancer Research Center
- 3. Seattle Cancer Care Alliance
- 4. University of Pittsburgh

Corresponding author:

Dr. Hannah Linden

hmlinden@uw.edu

825 Eastlake Ave E Seattle, WA 98109

Download English Version:

https://daneshyari.com/en/article/8612754

Download Persian Version:

https://daneshyari.com/article/8612754

<u>Daneshyari.com</u>